Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Samantha Winzenread

Physician Assistant Simpsonville, SC Physician Assistant

NPI 1659036119 CMS profile 11266139

11 Five Fork Plaza Ct Unit A, Simpsonville, SC 29681

Open in the dashboard

General payments

$6,701

283 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samantha Winzenread of Simpsonville, SC is reported in the CMS Open Payments database as having received $6,701 across 283 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,201 86
2024 General $1,787 76
2023 General $1,361 58
2022 General $1,352 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samantha Winzenread
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Samantha Winzenread were reported at $2,201. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Samantha Winzenread Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $1,352 $155 $48–$522 $149
2023 $1,361 $167 $52–$557 $160
2024 $1,787 $178 $55–$600 $164
2025 $2,201 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $1,249 61 payments
  2. Lilly USA, LLC $1,119 53 payments
  3. AbbVie, Inc. $1,023 40 payments
  4. AstraZeneca Pharmaceuticals LP $751 17 payments
  5. Pfizer Inc. $527 46 payments
  6. Antares Pharma, Inc. $409 2 payments
  7. ITI, Inc. $233 7 payments
  8. Dexcom, Inc. $222 4 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $196 5 payments
  10. Exact Sciences Corporation $151 10 payments
  11. Other $820 38 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,701 283 payments
Products named General payments · program years 2022–2025
  1. VRAYLAR $709 18 payments
  2. RYBELSUS $655 35 payments
  3. Ozempic $538 33 payments
  4. FARXIGA $523 11 payments
  5. MOUNJARO $508 28 payments
  6. NURTEC ODT $485 43 payments
  7. XYOSTED $409 2 payments
  8. JARDIANCE $398 18 payments
  9. Wegovy $312 13 payments
  10. ZAVZPRET $268 30 payments
  11. Other $3,314 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

2,421

Median for Physician Assistant: 241

Drug cost

$301,257

Median for Physician Assistant: $4,110

Branded share of claims

22.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 37 $54,353
Ozempic Semaglutide Brand 44 $54,283
Farxiga Dapagliflozin Propanediol Brand 37 $49,217
Jardiance Empagliflozin Brand 33 $42,890
Rybelsus Semaglutide Brand 20 $31,840
Eliquis Apixaban Brand 27 $29,126
Trulicity Dulaglutide Brand 11 $14,517
Gabapentin Generic 60 $2,011
Rosuvastatin Calcium Generic 138 $1,753
Albuterol Sulfate Hfa Albuterol Sulfate Brand 32 $1,622

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $222
$222 — —
ZEPBOUND
  • Lilly USA, LLC $188
$188 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $179
$179 37 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $118
$118 — —
Leqembi
  • Eisai Inc. $118
$118 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

283 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record